Oxidative pathways as a drug target for the treatment of autism (Q28295948)

Michael Berk

6

0 references

Bruce Tonge

Bruce Tonge

5

0 references

Olivia M. Dean

3

Olivia Dean

0 references

Seetal Dodd

2

Seetal Dodd

0 references

author name string

Kristi-Ann Villagonzalo

Expert Opinion on Therapeutic Targets

1

0 references

language of work or name

English

0 references

publication date

December 2010

0 references

published in

0 references

volume

14

0 references

issue

12

0 references

page(s)

1301-10

0 references

cites work

Systematic Review of Early Intensive Behavioral Interventions for Children With Autism

1 reference

https://api.crossref.org/works/10.1517/14728222.2010.528394

A national profile of the health care experiences and family impact of autism spectrum disorder among children in the United States, 2005-2006.

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Behaviour and emotional problems in toddlers with pervasive developmental disorders and developmental delay: associations with parental mental health and family functioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

The impact of behaviour problems on caregiver stress in young people with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Parents' experiences of home-based applied behavior analysis programs for young children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Pharmacotherapy of target symptoms in autistic spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Complementary and alternative medicine treatments for children with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Neurodegenerative diseases and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Glutathione: a novel treatment target in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Investigation of antioxidant enzymes in children with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Mitochondrial dysfunction in autism spectrum disorders: cause or effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Abnormal transmethylation/transsulfuration metabolism and DNA hypomethylation among parents of children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin--the antioxidant proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Mitochondrial disease in autism spectrum disorder patients: a cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Developmental regression and mitochondrial dysfunction in a child with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Epidemiology of autism spectrum disorder in Portugal: prevalence, clinical characterization, and medical conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Autism and mitochondrial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Is autism a disorder of fatty acid metabolism? Possible dysfunction of mitochondrial beta-oxidation by long chain acyl-CoA dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Relative carnitine deficiency in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Mitochondrial dysfunction in autism spectrum disorders: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Biomarkers of environmental toxicity and susceptibility in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

A prospective study of transsulfuration biomarkers in autistic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

A clinical and laboratory evaluation of methionine cycle-transsulfuration and androgen pathway markers in children with autistic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Abnormally high plasma levels of vitamin B6 in children with autism not taking supplements compared to controls not taking supplements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Folate and methionine metabolism in autism: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Evidence of toxicity, oxidative stress, and neuronal insult in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Immunological findings in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Prevalence of chronic gastrointestinal symptoms in children with autism and autistic spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Metabolic biomarkers related to oxidative stress and antioxidant status in Saudi autistic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Increased oxidative stress and altered activities of erythrocyte free radical scavenging enzymes in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Increased excretion of a lipid peroxidation biomarker in autism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

A preliminary trial of ascorbic acid as supplemental therapy for autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Sulfhydryl-reactive metals in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Biliary secretion of glutathione and of glutathione-metal complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Preliminary evidence for involvement of the folate gene polymorphism 19bp deletion-DHFR in occurrence of autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Analysis of case-parent trios at a locus with a deletion allele: association of GSTM1 with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Genetic variant of glutathione peroxidase 1 in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

SLC25A12 expression is associated with neurite outgrowth and is upregulated in the prefrontal cortex of autistic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Mitochondrial dysfunction in autistic patients with 15q inverted duplication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Altered calcium homeostasis in autism-spectrum disorders: evidence from biochemical and genetic studies of the mitochondrial aspartate/glutamate carrier AGC1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Carnosine and carnosine-related antioxidants: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

How environmental and genetic factors combine to cause autism: A redox/methylation hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Early behavioral intervention, brain plasticity, and the prevention of autism spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Treating the core features of autism: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Internet survey of treatments used by parents of children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Applied behavior analytic intervention for autism in early childhood: meta-analysis, meta-regression and dose-response meta-analysis of multiple outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Randomized, controlled trial of an intervention for toddlers with autism: the Early Start Denver Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Treatment incidence and patterns in children and adolescents with autism spectrum disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

The status of pharmacotherapy for autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Risperidone in children with autism: randomized, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

The effects of hyperbaric oxygen therapy on oxidative stress, inflammation, and symptoms in children with autism: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part A--medical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Chelation therapy and autism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394

Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2010.528394